Durvalumab in ≥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.Marina Chiara Garassino,Byoung Chul Cho,Joo-Hang Kim,Julien Mazieres,Jhanelle Elaine Gray,Paul Wheatley-Price,Keunchil Park,Ross A. Soo,Yifan Huang,Catherine Wadsworth,Phillip A. Dennis,Naiyer A. RizviJournal of Clinical Oncology(2018)引用 5|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要